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Valorisation 
This thesis aims to bring platelet function analysis closer to patients to optimize the patient 
diagnosis and treatment. Due to the limited tools for routine evaluation of platelet function 
in patients with bleeding diathesis, there is underestimated prevalence of platelet function 
disorders (PFDs). On the other hand, with the development and worldwide use of new 
antithrombotic drugs, new challenges come along with the clinical management of patients 
receiving antithrombotic therapy. Our research focuses on improving our knowledge of 
platelets in clinical diseases by the adoption of standardized and simplified strategies. 
Valorisation is an official name used by the Dutch government since 2009, to describe the 
process of creati ng value from knowledge by making knowledge suitable and/or available 
for economic and/or societal use and translating that knowledge into products, services, 
processes and entrepreneurial activity [1]. As our new strategies for platelet function 
assessment is still in its infancy, it takes time to realize its societal and economic benefit. In 
this chapter, we will introduce the scientific and societal background regarding our studies 
and discuss the potential contribution of scientific knowledge obtained from our studies to 
the development of research strategy and improvement of clinical practice.  
Platelet function disorders (PFDs) 
Underdiagnosis and burden 
The advances from research on platelet molecular and cell biology and (patho)physiology 
over the last few decades have not been adequately translated to clinical laboratory 
diagnosis [2]. The prevalence of inherited PFDs (IPFDs) among general population has not 
been established, likely because testing is time consuming and requires rapid processing of 
freshly collected blood samples [3]. The diagnosis of IPFDs is challenging due to the lack of 
defined diagnostic criterion. Prospective studies evaluating patients with bleeding disorders 
identified that IPFDs are as common as, or even greater than, von Willebrand disease (VWD) 
[4-8]. Among various IPFDs, platelet secretion and signal transduction defects are the most 
frequent [9, 10]. It was speculated that prevalence of some mild platelet secretion defects 
can be up to 1/100 [11]. The laboratory diagnosis of IPFDs places a significant burden on 
hematology laboratories [12]. 
Some IPFD-associated bleeding symptoms such as, excessive bruising and prolonged 
menses, are also quite common in the general population [13]. IPFDs are more commonly 
diagnosed in women, likely because the added haemostatic challenges of menstruation and 
Appendix II  
 
222 
 
childbirth affect the burden of living with a congenital platelet disorder and the likelihood 
of been referred for evaluation [14, 15]. A bleeding tendency in patients with a suspected 
or confirmed congenital PFDs impacts healthy status-related quality of life (HR-QoL), such 
as, decreased physical functioning, limitations in daily activities and social activities, 
decreased energy levels and fatigue, etc [16]. Even after extensive laboratory testing, as 
recommended by the International Society on Thrombosis and Haemostasis (ISTH) [17], 
many patients remain unrecognized. Accurate diagnosis can address prompt and 
appropriate treatment of patients with suspected IPFDs and minimize the associated 
bleeding risk, and therefore improve HR-QoL of these patients [18].  
Added values of our strategies to the diagnostic work-up of PFDs 
A half century after light transmission aggregometry (LTA) was developed [19], it remains 
the most commonly used method for evaluating platelet function, and its main use is to 
assess bleeding disorders. As LTA is a time-consuming and technically challenging technique 
that is affected by many pre-analytical and analytical variables, the methodological 
standardization of LTA is necessary [20]. The guidelines for standardization of LTA was 
provided by ISTH in 2013 [21], followed by the international guidelines on the diagnostic 
approach to inherited PFDs [17]. In the first-step screening of inherited PFDs, flow 
cytometry plays the complementary role for LTA in the assessment of platelet granule 
release and major platelet surface glycoproteins. Compared to LTA, Flow cytometry has 
multiple advantages in platelet function analysis: higher sensitivity, less sample volume 
needed and applicable to low platelet count samples. Therefore, it is quite useful for 
thrombocytopenia or pediatric samples [22]. Platelet flow cytometry has versatile utilities 
in diagnostic and therapeutic hematology [23], however, the complexed old-school sample 
processing and unstandardized technique hamper its application in wider clinical practice. 
As depicted in Chapter 2, our standardized protocol pushes flow cytometry towards the 
diagnostic routine for patients with PFDs. The sample processing and analysis can be 
performed in routine clinical scenarios by clinical lab technicians after simple training. Flow 
cytometry has shown added values in diagnostics of suspected IPFDs [24, 25]. The pre-
prepared test kits also make high throughput analysis of platelet function possible. 
Patient with inherited platelet GPVI defect have a mild to moderate bleeding phenotype [4]. 
The deficiency of platelet GPVI can be homozygous (GP6hom, an adenine insertion in exon 6 
of the GP6 gene) [26] or heterogenous (GP6het) [27-29]. GP6hom platelets completely lack 
GPVI surface expression, however, GP6het might have incomplete deficiency. GPVI 
quantification by flow cytometry can first screening the possible GPVI defects patients for 
further gene detection. The GPVI-specific agonist is critical for assessment of GPVI 
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deficiency by flow cytometry. The current widely used GPVI agonists (CRP-XL) was only 
produced by one lab and has variation between batches because of the final unstandardized 
cross-link step. The synthetic triple-helical collagen peptide (STH-CP) designed by us, as 
described in Chapter 3, provides a good alternative for CRP-XL by standardization of the 
synthesis procedures, though further studies are still needed to determine the inter-batch 
variation of STH-CP. CRP-XL is instable after dilution. The relatively low seasonal variation 
of our STH-CP compared to CRP-XL implies that our new peptide might be more suitable for 
the long-term clinical trials. Flow cytometric analysis of platelet GPVI-mediated function 
facilitates the investigation of GPVI-associated defects in research and diagnostic 
laboratories.  
Flow cytometry provides a superior way to evaluate platelet function in anticoagulant blood. 
We developed another new strategy, which is sensitive, simple, fast and need minimum 
sample volume, to investigate platelet secretion kinetics in coagulant blood. When 
coagulation triggers are used, coagulation is initiated first and then platelets are activated 
by generated thrombin. Thus, coagulation can be evaluated together with platelet 
activation. However, if direct platelet agonists are used, platelet dysfunction can be 
assessed directly. The initial validation in a specific patient population – multiple myeloma 
(MM) (as presented in Chapter 5) - demonstrated the usefulness of this new strategy in 
determining acquired platelet secretion defects in patients with hematologic disorders as 
well as thrombocytopenia. Platelet dysfunction might be an important indicator of disease 
progress or prognosis. The analysis platform is portable, affordable and can be easily 
implemented to any clinical laboratory. Such strategy would contribute to further 
understanding of platelet function in various clinical diseases. 
 Antithrombotic therapy  
Deadly burden of thrombosis  
Thrombosis can be divided into arterial and venous thrombosis. Ischemic heart disease and 
stroke, comprise the major arterial thrombosis, account for 1 in 4 deaths worldwide in 2010 
and are one of the leading causes of years of life lost due to premature mortality [30, 31]. 
Data about the worldwide burden of venous thromboembolism (VTE) is limited, probably 
due to the multifactorial nature of death attributable to VTE [31]. In six EU countries, the 
estimated attack rate was 148 per 100,000 person-years and 95 per 100,000 person-years 
for deep vein thrombosis (DVT) and pulmonary embolism (PE), respectively, [32]. 
Retrospective data showed that around 5%-10% of in-hospital death are a direct result of 
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PE [33, 34]. In addition to the risk of sudden death, VTE is associated with long-term 
morbidity and reduced survival [35-37]. 
Management of antithrombotic therapy 
Treatment paradigms have been changing with the evolving knowledge about the roles of 
platelets in venous thrombosis and thrombin in arterial thrombosis [38]. Despite new 
antithrombotic drugs, such as direct oral anticoagulants (DOACs) and newer antiplatelet 
drugs, show better benefit-risk profiles compared to traditional antithrombotic agents, 
there remains an unmet clinical need for appropriate strategy that can achieve a balance 
between the benefit of treatment and the risk of thrombosis and bleeding [38, 39]. The 
standard dose of antithrombotic agents, which suits normal patients, might be underdose 
or overdose for specific patients. Monitoring of antithrombotic therapy is helpful for certain 
patients to sustain the efficacy without excessive bleeding. Indication for determining 
antithrombotic drug levels can be considered in 2 categories: (1) determine the optimal 
dose for some patient populations, such as those with weight extremes, renal insufficiency, 
etc.; (2) critical clinical situations, such as major bleeding or need for emergent or elective 
surgery [40].  
Monitoring of low molecular weight heparins (LMWHs) in specific patients 
Due to the high risk of thromboembolic disease for hospitalized patients, LMWHs are 
commonly used in clinical practice. Critically ill patients in intensive care unit (ICU) have a 
greater risk of thrombotic events and are usually treated with LMWH [41]. Because ICU 
patients have altered pharmacokinetic and pharmacodynamic variability, this can lead to 
unpredictable drug effects and increased potential for adverse drug effects [42]. Therefore, 
monitoring of antithrombotic therapy is necessary for these patients. Although anti-Xa is 
widely available for LMWH monitoring in clinical laboratories, it has important limitations, 
which might affect the interpretation of results [43]. The development of our simple and 
cost-effective strategy contributes to more efficient and safer clinical anticoagulation 
management. The findings presented in Chapter 6 indicated that our new strategy 
(coagulation-induced platelet activation) has great potential for determining the overall 
anticoagulation effects of LMWH as it strongly correlated with the results of TG test. This 
new strategy may be used to differentiate the effects of different LMWH and therefore 
screen the most effective for individual patients in the future. Furthermore, this strategy 
may be easily implemented to routine clinical anticoagulation management as it is 
technically simple and fast. Compared to anti-Xa and TG assay, our new strategy uses whole 
blood which is closer to physiological conditions and might provide more comprehensive 
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information. However, it is unknown whether results of this new strategy are clinically 
relevant and further large studies are needed to investigate whether there is any 
association between experimental results and bleeding or thrombotic events. 
Fast clinical decision-making based on results of haemostasis assays 
For patients who receive DOAC for long-term prevention of VTE recurrence or stroke in AF, 
urgent surgery or intervention is necessary under certain conditions, such as life-
threatening haemorrhage, thrombotic events or trauma. It is important to determine the 
presence of DOACs as quickly as possible in these patients. The availability of rapid 
turnaround DOAC tests could help clinicians with fast decision-making: proceed with 
surgery or use costly reversal agents. Although DOAC-specific assays are reliable and 
reproducible in different clinical laboratories [44], these assays use plasma instead of whole 
blood and have relatively long turnaround time (approximately 35 minutes) [45]. Point-of-
care tests, which use small quantities of whole blood to assess the presence of DOACs, are 
under various stages of development. Our new strategy was sensitive to detect the effects 
of low-to-medium concentrations of DOACs (as described in Chapter 7). It is promising to 
launch clinical trial to validate the utility of this new strategy in monitoring of DOACs and 
compared with the commonly used method, high-performance liquid chromatography-
coupled tandem mass spectrometry (HPLC-MS/MS), which is expensive, complex and time-
consuming. 
Conclusion 
Research performed in this thesis aims to bring platelet function assessment to the patients 
via standardization and innovation of the existed technologies. Our findings here is just the 
first step to the final goal: fulfill the clinical values (diagnostic, monitoring, etc.) of our 
optimized tests and improve the management of patients.   
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